View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBionomics 将来の成長Future 基準チェック /06現在、 Bionomicsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報-36.0%収益成長率n/aEPS成長率Biotechs 収益成長23.2%収益成長率-5.3%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日07 Aug 2023今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (80% average weekly change). Earnings are forecast to decline by an average of 36% per year for the foreseeable future. Market cap is less than US$10m (€8.72m market cap, or US$9.42m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$49m net loss in 2 years). Shareholders have been diluted in the past year (8.5% increase in shares outstanding). Revenue is less than US$5m (AU$6.0m revenue, or US$3.9m).お知らせ • Aug 24Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress DisorderBionomics Limited announced that the last patient last visit has been completed in its Phase 2 ATTUNE study in PTSD, and disclosed timing of the End of Phase 2 (EoPh2) meeting to review advancing BNC210 into Phase 3 program in patients with SAD. The Phase 2b ATTUNE study (NCT04951076) is a double-blind, placebo-controlled, randomized study of twice daily BNC210 as monotherapy treatment for PTSD. The primary endpoint is change in a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity scores from baseline to week 12 compared to placebo. Secondary endpoints include change from baseline to week 12 compared to placebo on the PTSD-checklist (PCL-5), anxiety (Hamilton Anxiety Rating Scale, HAM-A), depression (Montgomery-Asberg Depression Rating Scale, MADRS), Clinician Global Impression (CGI), Patient Global Impression (PGI), sleep (Insomnia Severity Index, ISI) and disability (Sheehan Disability Scale, SDS) scales. Approximately 200 participants have been enrolled at 27 sites in the United States and 7 sites in the United Kingdom, and topline results are anticipated by the end of September 2023. The EoPh2 meeting to discuss advancing BNC210 into Phase 3 development as an acute treatment for SAD has been scheduled for mid-September 2023. At this meeting, Bionomics will discuss with the FDA its plans for a Phase 3 program that would support the submission of a new drug application for BNC210 for the treatment of SAD. The Company believes that the results from Phase 2 PREVAIL study support the progression of BNC210 into Phase 3 and plans to provide an update by the end of 2023 following the receipt of formal meeting minutes from the FDA.New Risk • Aug 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.85m (US$9.71m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (72% average weekly change). Earnings are forecast to decline by an average of 36% per year for the foreseeable future. Market cap is less than US$10m (€8.85m market cap, or US$9.71m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$49m net loss in 2 years). Shareholders have been diluted in the past year (8.5% increase in shares outstanding). Revenue is less than US$5m (AU$6.0m revenue, or US$4.0m).お知らせ • Jul 04+ 1 more updateBionomics Limited Appoints Tim Cunningham as Chief Financial OfficerBionomics Limited announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive member of the Board since 1 September 2016 and Chair of the Audit & Risk Committee, has been appointed Non-Executive Chair of the Board, effective from 1 July 2023. Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director. Tim Cunningham of Danforth Associates has been appointed Chief Financial Officer effective 1 July 2023. This appointment is in continuation to the ongoing expansion of the leadership team that began in 2023 with the appointment of Julie Kerner, Ph.D., as Senior Vice President of Business Operations, and Atul R. Mahableshwarkar, MD, as the Acting Chief Medical Officer. The Company has also engaged Francisco Bejar as a strategic advisor to head the business development efforts in the U.S. and abroad, whilst Connor Bernstein, Vice President, Strategy and Development, steps down from his role with effect from 30 June 2023. Mr. Fisheris an experienced corporate advisor and public company director, with a proven track record for implementing strategies that enhance shareholder value. His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice. He is currently a Non-Executive Director and Chair of Centrepoint Alliance Limited and Non-Executive Director and Chair of the Audit and Risk Committee of Thorney Technologies Limited Mr. Cunningham has served as a Chief Financial Officer Consultant at Danforth, a strategic finance and operations firm with a focus on life sciences companies, since September 2020, where he provides chief financial officer consulting services to both public and private pharma and biotechnology companies. Prior to joining Danforth, Mr. Cunningham served as Chief Financial Officer at Organogenesis (NASDAQ:ORGO), where he took the company public and raised over US$250M in equity and debt financing to facilitate the company’s growth. He has held leadership positions with several different public and private companies over the course of his career, which began at KPMG in NY followed by PwC Boston. Mr. Cunningham holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the state of Florida. Dr. Kerner brings over 15 years of experience where under her leadership companies created portfolio and platform strategies, built new therapeutic areas, filed over 10 IND/CTAs, conducted proof of concept and Phase 3 trials, and launched multiple therapeutics. Dr Kerner has worked at Biogen, AVROBIO, Wave Life Sciences and most recently Fulcrum Therapeutics and Aliada Therapeutics, where she was responsible for driving pipeline strategy and program leadership. Dr. Kerner is a board member of Newton Wellesley Hospital, National Braille Press, and the U.S. Neuroacanthocytosis advocacy Inc. Dr. Mahableshwarkar is a board-certified psychiatrist with over 20 years of strategic, developmental, and regulatory experience in large global and small startup companies who have submitted INDs and NDAs leading to drug approvals. He has had leadership roles as Chief Medical Officer and Senior Vice President/Vice President for Clinical Development in Emalex Biosciences and BlackThorn Therapeutics, where he provided strategy and oversight of the clinical program from proof of concept to drug approval. The company has also engaged Mr. Francisco Bejar as a Strategic Business Development Advisor to lead the Company’s partnering efforts for BNC210, the company’s preclinical assets (KV3 and Nav1.7/1.8 programs) and our legacy oncology portfolio both in the U.S. and ex-U.S.Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share. Net loss: AU$16.2m (loss widened 24% from 1H 2022). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.Board Change • Feb 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO, President & Director Spyros Papapetropoulos was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 18High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Aug 26Full year 2022 earnings released: AU$0.016 loss per share (vs AU$0.011 loss in FY 2021)Full year 2022 results: AU$0.016 loss per share (down from AU$0.011 loss in FY 2021). Net loss: AU$21.8m (loss widened 150% from FY 2021). Over the next year, revenue is forecast to grow 44%, compared to a 10% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings.Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Jan 07High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Board Change • Dec 31High number of new directorsMember of Clinical Advisory Board Srini Rao was the last director to join the board, commencing their role in 2021.Reported Earnings • Aug 26Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)Full year 2021 results: Net loss: AU$8.70m (loss widened 50% from FY 2020). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.Executive Departure • Mar 25Legal Counsel & Company Secretary has left the companyOn the 23rd of March, Jack Moschakis' tenure as Legal Counsel & Company Secretary ended after 5.9 years in the role. As of December 2020, Jack personally held only 35.52k shares (€2.7k worth at the time). A total of 2 executives have left over the last 12 months.Analyst Estimate Surprise Post Earnings • Mar 04Revenue beats expectationsRevenue exceeded analyst estimates by 43%.Is New 90 Day High Low • Feb 19New 90-day high: €0.27The company is up 309% from its price of €0.066 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.業績と収益の成長予測DB:B1N - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20255-60-21N/A26/30/20245-39-17N/A26/30/20235-29-20N/A212/31/20226-25-18-18N/A9/30/20226-23-20-20N/A6/30/20226-22-22-22N/A3/31/20223-22-20-20N/A12/31/20210-22-19-19N/A9/30/20211-15-13-13N/A6/30/20211-9-8-8N/A3/31/20211-4N/AN/AN/A12/31/202021-5-5N/A9/30/20202-3-5-4N/A6/30/20203-6-4-4N/A12/31/20196-5-9-9N/A9/30/20197-8-13-12N/A6/30/20197-10-16-16N/A3/31/20198-20-15-15N/A12/31/20188-28-15-14N/A9/30/201810-27-18-17N/A6/30/201812-25-21-20N/A3/31/201819-15-16-16N/A12/31/201727-6-11-11N/A9/30/201727-6-6-6N/A6/30/201727-7-2-1N/A3/31/201722-12-7-7N/A12/31/201616-17-13-13N/A9/30/201618-17N/A-14N/A6/30/201619-17N/A-15N/A3/31/201619-19N/A-17N/A12/31/201518-21N/A-18N/A9/30/201517-19N/A-6N/A6/30/201515-17N/A5N/A3/31/201522-6N/A6N/A12/31/2014294N/A7N/A9/30/2014284N/A-3N/A6/30/2014273N/A-13N/A3/31/201419-5N/A-9N/A12/31/201312-13N/A-5N/A9/30/201312-11N/A-8N/A6/30/201312-10N/A-10N/A3/31/201313-7N/A-9N/A12/31/201213-4N/A-9N/A9/30/201212-3N/A-6N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: B1N今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: B1N今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: B1N今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: B1Nの収益は今後 3 年間で減少すると予想されています (年間-5.3% )。高い収益成長: B1Nの収益は今後 3 年間で減少すると予測されています (年間-5.3% )。一株当たり利益成長率予想将来の株主資本利益率将来のROE: B1Nの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/09/01 00:58終値2023/08/24 00:00収益2022/12/31年間収益2022/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Neuphoria Therapeutics Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Tanushree JainBell PotterEsther Lannie HongBerenbergKatherine GenisEdison Investment Research2 その他のアナリストを表示
New Risk • Aug 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (80% average weekly change). Earnings are forecast to decline by an average of 36% per year for the foreseeable future. Market cap is less than US$10m (€8.72m market cap, or US$9.42m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (AU$49m net loss in 2 years). Shareholders have been diluted in the past year (8.5% increase in shares outstanding). Revenue is less than US$5m (AU$6.0m revenue, or US$3.9m).
お知らせ • Aug 24Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress DisorderBionomics Limited announced that the last patient last visit has been completed in its Phase 2 ATTUNE study in PTSD, and disclosed timing of the End of Phase 2 (EoPh2) meeting to review advancing BNC210 into Phase 3 program in patients with SAD. The Phase 2b ATTUNE study (NCT04951076) is a double-blind, placebo-controlled, randomized study of twice daily BNC210 as monotherapy treatment for PTSD. The primary endpoint is change in a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity scores from baseline to week 12 compared to placebo. Secondary endpoints include change from baseline to week 12 compared to placebo on the PTSD-checklist (PCL-5), anxiety (Hamilton Anxiety Rating Scale, HAM-A), depression (Montgomery-Asberg Depression Rating Scale, MADRS), Clinician Global Impression (CGI), Patient Global Impression (PGI), sleep (Insomnia Severity Index, ISI) and disability (Sheehan Disability Scale, SDS) scales. Approximately 200 participants have been enrolled at 27 sites in the United States and 7 sites in the United Kingdom, and topline results are anticipated by the end of September 2023. The EoPh2 meeting to discuss advancing BNC210 into Phase 3 development as an acute treatment for SAD has been scheduled for mid-September 2023. At this meeting, Bionomics will discuss with the FDA its plans for a Phase 3 program that would support the submission of a new drug application for BNC210 for the treatment of SAD. The Company believes that the results from Phase 2 PREVAIL study support the progression of BNC210 into Phase 3 and plans to provide an update by the end of 2023 following the receipt of formal meeting minutes from the FDA.
New Risk • Aug 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.85m (US$9.71m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (72% average weekly change). Earnings are forecast to decline by an average of 36% per year for the foreseeable future. Market cap is less than US$10m (€8.85m market cap, or US$9.71m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (AU$49m net loss in 2 years). Shareholders have been diluted in the past year (8.5% increase in shares outstanding). Revenue is less than US$5m (AU$6.0m revenue, or US$4.0m).
お知らせ • Jul 04+ 1 more updateBionomics Limited Appoints Tim Cunningham as Chief Financial OfficerBionomics Limited announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive member of the Board since 1 September 2016 and Chair of the Audit & Risk Committee, has been appointed Non-Executive Chair of the Board, effective from 1 July 2023. Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director. Tim Cunningham of Danforth Associates has been appointed Chief Financial Officer effective 1 July 2023. This appointment is in continuation to the ongoing expansion of the leadership team that began in 2023 with the appointment of Julie Kerner, Ph.D., as Senior Vice President of Business Operations, and Atul R. Mahableshwarkar, MD, as the Acting Chief Medical Officer. The Company has also engaged Francisco Bejar as a strategic advisor to head the business development efforts in the U.S. and abroad, whilst Connor Bernstein, Vice President, Strategy and Development, steps down from his role with effect from 30 June 2023. Mr. Fisheris an experienced corporate advisor and public company director, with a proven track record for implementing strategies that enhance shareholder value. His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice. He is currently a Non-Executive Director and Chair of Centrepoint Alliance Limited and Non-Executive Director and Chair of the Audit and Risk Committee of Thorney Technologies Limited Mr. Cunningham has served as a Chief Financial Officer Consultant at Danforth, a strategic finance and operations firm with a focus on life sciences companies, since September 2020, where he provides chief financial officer consulting services to both public and private pharma and biotechnology companies. Prior to joining Danforth, Mr. Cunningham served as Chief Financial Officer at Organogenesis (NASDAQ:ORGO), where he took the company public and raised over US$250M in equity and debt financing to facilitate the company’s growth. He has held leadership positions with several different public and private companies over the course of his career, which began at KPMG in NY followed by PwC Boston. Mr. Cunningham holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the state of Florida. Dr. Kerner brings over 15 years of experience where under her leadership companies created portfolio and platform strategies, built new therapeutic areas, filed over 10 IND/CTAs, conducted proof of concept and Phase 3 trials, and launched multiple therapeutics. Dr Kerner has worked at Biogen, AVROBIO, Wave Life Sciences and most recently Fulcrum Therapeutics and Aliada Therapeutics, where she was responsible for driving pipeline strategy and program leadership. Dr. Kerner is a board member of Newton Wellesley Hospital, National Braille Press, and the U.S. Neuroacanthocytosis advocacy Inc. Dr. Mahableshwarkar is a board-certified psychiatrist with over 20 years of strategic, developmental, and regulatory experience in large global and small startup companies who have submitted INDs and NDAs leading to drug approvals. He has had leadership roles as Chief Medical Officer and Senior Vice President/Vice President for Clinical Development in Emalex Biosciences and BlackThorn Therapeutics, where he provided strategy and oversight of the clinical program from proof of concept to drug approval. The company has also engaged Mr. Francisco Bejar as a Strategic Business Development Advisor to lead the Company’s partnering efforts for BNC210, the company’s preclinical assets (KV3 and Nav1.7/1.8 programs) and our legacy oncology portfolio both in the U.S. and ex-U.S.
Reported Earnings • Feb 24First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)First half 2023 results: AU$0.012 loss per share. Net loss: AU$16.2m (loss widened 24% from 1H 2022). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Europe.
Board Change • Feb 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO, President & Director Spyros Papapetropoulos was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 18High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Aug 26Full year 2022 earnings released: AU$0.016 loss per share (vs AU$0.011 loss in FY 2021)Full year 2022 results: AU$0.016 loss per share (down from AU$0.011 loss in FY 2021). Net loss: AU$21.8m (loss widened 150% from FY 2021). Over the next year, revenue is forecast to grow 44%, compared to a 10% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings.
Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Jan 07High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. 1 highly experienced director. Executive Chairman Errol B. De Souza is the most experienced director on the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Board Change • Dec 31High number of new directorsMember of Clinical Advisory Board Srini Rao was the last director to join the board, commencing their role in 2021.
Reported Earnings • Aug 26Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)Full year 2021 results: Net loss: AU$8.70m (loss widened 50% from FY 2020). Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
Executive Departure • Mar 25Legal Counsel & Company Secretary has left the companyOn the 23rd of March, Jack Moschakis' tenure as Legal Counsel & Company Secretary ended after 5.9 years in the role. As of December 2020, Jack personally held only 35.52k shares (€2.7k worth at the time). A total of 2 executives have left over the last 12 months.
Analyst Estimate Surprise Post Earnings • Mar 04Revenue beats expectationsRevenue exceeded analyst estimates by 43%.
Is New 90 Day High Low • Feb 19New 90-day high: €0.27The company is up 309% from its price of €0.066 on 20 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.